Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise, ImpediMed surges 99% on NCCN guidelines update
Health & Biotech
ASX Health Stocks: Patrys crashes after Phase 1 delayed till 2024, Nova Eye surges 20pc on FDA OK
Health & Biotech
Nova Eye Medical secures FDA clearance for iTrack Advance to treat glaucoma
Health & Biotech
Argenica secures significant non-dilutive funding for preclinical studies into newborn brain injury
Health & Biotech
ASX Health Stocks: Cyclopharm sends reply to FDA, the final step before potential approval
Health & Biotech
PharmAust completes patient enrolment for MPL trial with sights on US$3.6 billion Motor Neurone Disease market
Health & Biotech
EZZ launches Amazon online store and releases three new products
Health & Biotech
Health Kick Podcast: EZZ signs agreement with University of Auckland to conduct product research
Health & Biotech
ASX Health Stocks: Woolworths’ subsidiary partners with Telehealth stock Global Health, share price up 5pc
Health & Biotech
PharmAust’s MND trial progressing with ‘stable’ patient moving to higher dosage
Health & Biotech
ASX Biotech Stocks: Noxopharm eyes new mRNA product with market forecast to hit US$128 billion by 2030
Health & Biotech
Nova Eye Medical eyes strong growth as it awaits FDA approval for iTrack™ Advance
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.